dipyridamole has been researched along with tyrosine in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (16.67) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (83.33) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
El-Gamel, S; Müller, WE; Wollert, U | 1 |
Mohammad, SF; Solen, KA; Sukavaneshvar, S | 1 |
Ito, H; Kimura, Y; Ozeki, Y; Sudo, T | 1 |
Azevedo, R; Beierlein, W; Dietz, K; Straub, A; Wendel, HP; Ziemer, G | 1 |
Fontana, P | 1 |
1 review(s) available for dipyridamole and tyrosine
Article | Year |
---|---|
[Update on antithrombotic treatments in arterial diseases].
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Arteriosclerosis; Aspirin; Dipyridamole; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Pyridines; Thrombosis; Tirofiban; Treatment Outcome; Tyrosine | 2007 |
5 other study(ies) available for dipyridamole and tyrosine
Article | Year |
---|---|
Optical studies on the specific interaction of dipyridamole with alpha 1-acid glycoprotein (orosomucoid).
Topics: Chemical Phenomena; Chemistry, Physical; Circular Dichroism; Dialysis; Dipyridamole; Humans; In Vitro Techniques; Orosomucoid; Protein Binding; Protein Conformation; Spectrophotometry, Ultraviolet; Tryptophan; Tyrosine | 1982 |
An in-vitro model to study device-induced thrombosis and embolism: evaluation of the efficacy of tirofiban, aspirin, and dipyridamole.
Topics: Animals; Anticoagulants; Aspirin; Blood Flow Velocity; Cattle; Dipyridamole; Dose-Response Relationship, Drug; Edetic Acid; Embolism; Equipment and Supplies; Equipment Design; Evaluation Studies as Topic; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Scattering, Radiation; Stents; Thrombosis; Tirofiban; Tyrosine | 2000 |
[New antiplatelet agents].
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidogrel; Cyclooxygenase Inhibitors; Dipyridamole; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Phosphodiesterase Inhibitors; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Ticlopidine; Tirofiban; Tyrosine | 2000 |
Estimation of anti-platelet drugs on human platelet aggregation with a novel whole blood aggregometer by a screen filtration pressure method.
Topics: Adenosine Diphosphate; Amino Acid Chloromethyl Ketones; Aspirin; Blood Coagulation; Blood Platelets; Cilostazol; Collagen; Dipyridamole; Filtration; Heparin; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Pressure; Tetrazoles; Time Factors; Tirofiban; Tyrosine | 2001 |
Tirofiban (Aggrastat) protects platelets and decreases platelet-granulocyte binding in an extracorporeal circulation model.
Topics: Aprotinin; Binding, Competitive; Biomarkers; Blood Platelets; Dipyridamole; Eptifibatide; Extracorporeal Circulation; Flow Cytometry; Granulocytes; Humans; Male; Milrinone; P-Selectin; Peptides; Phosphodiesterase Inhibitors; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Serine Proteinase Inhibitors; Tirofiban; Tyrosine | 2006 |